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Abstract: The characterization of an allergen is a troublesome and difficult process,
as it requires both the precise biochemical characterization of a (glyco)protein mole-
cule and the establishment of its susceptibility to IgE antibodies, as they are the main
link to histamine release in some hypersensitivity states (type I allergies). As the
characterization of an allergen includes molecular weight determination of the aller-
genic molecule, its structure determination, physicochemical properties, IgE bind-
ing properties of the allergen molecule, and its allergenicity, an overal review of
which biochemical and immunochemical methods are used in achieving this goal
are presented in this paper. The information on the molecular level on the stuctures
of allergens indicates that allergens are considerably heterogeneous protein struc-
tures, and that there is no particular aminoacid sequence which is responsible for the
allergenicity. Therefore, information gained from detailed structural, functional and
immunochemical studies of these intriguing molecules, which nowadays modulate a
variety of pathophysiological conditions, would greatly improve our understanding
of the underlying disease mechanisms, and the way to handle them.
Keywords: allergen, characterization, allergy, immunoglobulin E, recombinant al-
lergen.
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1. INTRODUCTION
When a patient becomes allergic to one of the well recognized sources of aller-
gens, an IgE antibody response has been produced to one or more of the proteins
that are produced by mites, trees, grass, cats of fungi.
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The term ”allergen” came to be used selectively for proteins that cause
supersensitivity, i.e., an allergen is an antigen which gives rise to hypersensitivity.
A great majority of allergens are proteins the sizes of which range in molecular
weight from 10 to 70 kDa. They are all freely soluble in aqueous solutions and have
diverse biological functions. Cloning has revealed sequence homology between al-
lergens and diverse proteins, including enzymes, carrier proteins, calycines and
pollen recognition proteins. Any allergen can be described either by its source or
by the nature of specific proteins. Same of the functions tied to the corresponding
allergens are given in Table I.
TABLE I. Potential biochemical properties of some of the previously described major allergens. The
appropriate literature references are mentioned in the text
Allergen Function
Grass pollen
Group 1 Endoglucanase (expansin)
Tree pollen Jun a 3 Endo -1,3-glucanases
Tree pollen Bet v 2 and allergens homologous to Bet v 2 Profilin
Dust mites
Group 2 Cholesterol binding
Group 1 Cysteine proteasae
Group 14 Lipid binding
Mammals and insects
Lipocalins Lipid binding
Peach fruit
Pru p 3 Lipid transfer protein
Kiwi fruit
Act c 2 Antifungal activity
There is no doubt that the methods used in allergen characterization are com-
plex, as allergen characterization is a difficult and troublesome task. The aims of
the characterization of any allergen should include:
 physicochemical characterization and structure determination of the mole-
cule
 insight into the potential biological function of a given molecule
 immunological characterization and allergenicity proven by in vitro and in
vivo methods (IgE binding from the serum of an allergenic patient, ability to
release histamine, ability to stimulate specific T-cell proliferation).
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2. PHYSICOCHEMICAL CHARACTERIZATION
Probably one of the most popular and the most common techniques in the
characterization of an allergen, isolated from natural sources, is Laemmli SDS
PAGE followed by Western blotting.1 The powerful resolution of sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS PAGE) usually makes it the first
choice method for the preliminary screening of potential allergens of a certain
source. By using an appropriate set of protein markers, this method enables a cali-
bration curve to be constructed and the apparent molecular weight of a protein (i.e.,
its mobility in different polyacrylamide gels) to be determined.
However, this method is not sufficiently accurate and can result in a large overes-
timation of a molecular weight (Mw) or an underestimation of a Mw, especially in cases
of highly basic proteins, such as Art v 1,2 or highly acidic proteins,3 where abnormal
SDS binding occurs, leading to ”false” results. Sometimes, especially when dealing
with a monomeric protein containing a large number of disulfide bridges (such as the
major kiwi allergen Act c 2), its molecular weight can also be misjudged and can vary
depending on the presence of a reducing agent, due to the more compact fold in its
unreduced form and, therefore, higher mobility in a polyacrylamide gel.4 However, al-
though for such anomalous cases, Tris-tricine systems5 can be more appropriate, they
are not in general use in allergen characterization.
Native PAGEs are not particularly applicable for the purpose of allergen char-
acterization, due to the low resolution of the separation. However, they (both ana-
lytical and preparative) can also find application in the characterization of native
and recombinant counterparts, such as in the case of Phl p 2.6
Capillary electrophoresis is also capable of separating proteins and peptides
and includes the possibility of online-coupling to mass spectrometers.
As one-dimensional electrophoretic analysis of an allergen is usually not suf-
ficient to characterize the individual specificity of the IgE response to certain aller-
gens, two-dimensional electrophoreses are the methods of choice. They can both
separate and define the physico-chemical characteristics of allergens, as they give
isoelectric points and molecular mass of the analyzed samples. By means of 2D
PAGE it is possible to characterize different isoforms of a particular allergen the
so-called isoallergenic forms, as described for Fes p 4, a basic allergen of Festuca
pratensis pollen.7 For example, latex-glove proteins, which are allergens, can be
absent from the sap extracts and the sensitization of these allergens could be under-
estimated. Individual 2-D analysis of the sensitization to latex allergens is useful to
define the best allergen mixture required for diagnosis and needed for individual
therapy monitoring.8 With the introduction of immobilized pH gradient, high reso-
lution and reproducible 2D electrophoresis could be obtained. It is possible to dis-
tinguish an enormous number of IgE binding proteins by means of 2D PAGE, espe-
cially when the immobilized ampholytes are used in the first dimension. This tech-
nique was also applied to separate the allergens of Dactylis glomerata pollen.9
METHODS FOR ALLERGEN CHARACTERIZATION 349
However, the troublesome and time-consuming 2D PAGEs are not suitable for
the rapid screening of potential allergens, therefore, the one-dimensional, usually
reducing, SDS PAGE conditions are frequently the first choice of analytical bio-
chemists when searching for a new allergen.
Once the protein of interest has been identified, its properties, such as pI value,
could be determined by IEF using ampholytes or immobilized variants, as already
mentioned. Perhaps, the final point of a preliminary characterization of an allergen
would be to accurately determine its Mw. In such cases, the usually employed size
exclusion chromatography, calibrated with a set of calibration proteins, could also
be prone to error, especially regarding highly glycosylated proteins, the glyco
component of which is usually voluminous.
However, size exclusion chromatography finds its application in comparisons
of natural and recombinant counterparts. It is a great task to make a recombinant al-
lergen. Very often, such a protein is produced in the form of inclusion bodies,
hence, it is necessary to refold it correctly, as the correct 3D structure of an allergen
is necessary for its biological activity (i.e., IgE binding and subsequent histamine
release from basophiles). In such cases, a comparison of the SEC profiles of re-
combinant proteins with those of natural ones would be a useful method to obtain
an indication of the correct folding. As SEC mobility is highly dependent on the
correct shape of the protein globule, the SEC mobility is not the same for properly
folded (globular) and unfolded (random coil) proteins.
3. THE PRIMARY STRUCTURE AND DETERMINATION OF POST-TRANSLATIONAL
MODIFICATIONS
During the last decade, since the introduction of electrospray ionization
(ESI)10 and MALDI11 for large biomolecules, these techniques have become the
most powerful tools for protein identification and characterization.
The method of choice for an accurate Mw determination is a mass spectrome-
try technique suitable for proteins, such as MALDI MS. As this is basically the
mass spectrometry of (digested) protein samples, it could also be appicable for the
purpose of identification of a known allergen, if the total sequence of the protein is
available from a database.
Before the development of mass spectrometry for the analysis of biomo-
lecules, protein sequences were determined by chemical or enzymatic methods,
such as Edman degradation12 or amino acid analysis.13 The limitation of the
Edman degradation is its inability to analyze peptides lacking a free N-termini.
Furthermore, samples containing more than one peptide having a free N-terminus
are problematic due to overlapping of the results. Nowadays, de novo sequenc-
ing14 presents a new alternative to these methods and is capable of assigning pep-
tide sequences to fragment mass spectra without the need for any database.
Peptide mass fingerprints are the fastest method for identifying proteins re-
covered from 2-D PAGE. After gel electrophoresis, the protein spots are excised,
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washed and digested with a specific protease15 (Table II). The generated peptides
are subjected to mass spectrometry (MALDI-MS). The basic principle of this tech-
nique is the comparison of the measured peptide masses with calculated peptide
masses from database entries. Every protein results in a unique set of peptide
masses after cleavage with a specific protease. In the best case, only a few peptide
masses are required for reliable protein identification. The same approach, the gen-
eration of peptide fingerprints, is used when assessing the primary amino acid se-
quence of an unknown protein by Edman degradation. The proteases listed in Ta-
ble II are the most frequently used for this purpose. The enzymatic digestion usu-
ally takes advantage over chemical methods, due to the mild conditions and higher
specificity.
TABLE II. Overview of the most frequently used proteases in protein analysis
Endopeptidase Type Specificity pH range Inhibitors
Chymotrypsin Serine Y, F, W 1.5  8.5 Aprotinin, DFP, PMSF
Trypsin Serine R, K 7.5  9.0 TLCK, DFP, PMSF
Glu C Serine D, E 7.5  8.5 DFP
Lys C Serine K 7.5  8.5 DEFG,Aprotinin,Leupeptin
Arg C Cysteine R 7.5  8.5 EDTA,Citrate
Concerning the glycocomponent of an allergen, controversy exists among
allergologists in regards to how much the glycocomponent contributes to the clini-
cal significance of an allergen.
The covalent addition of sugar moieties to the polypeptide backbone of pro-
teins is one of the most widely occuring co- and post-translational modifications. It
is commonly found in a broad range of organisms and in a variety of different
forms. Glycoproteins are present inside cells, e.g., the cytoplasm and the inner
subcellular compartments, as well as outside cells, e.g., in extracellular matrices.
Glycosylation is a major secondary modification of proteins and adds another
dimension to the structural diversity, beyond that determined by genetic variation.
Two principal kinds of proteoglycans exist, N-linked and O-linked, which are
formed by different enzymatic pathways and comprise different carbohydrate
structures. N-glycans have attracted more attention than O-glycans during the past
decade, and several pollen allergens have been found to carry N-linked glycans.
The functional consequences of glycosylation and the diversity it confers are, how-
ever, still poorly understood.
Differences in allergenic glycoproteins include the amino acid residue of the
polypeptide backbone to which they are connected, the composition of the mono-
saccharide, the reducing sugar unit, the position and anomeric form of linkages be-
tween the individual sugar residues and the sequence of the monomeric units, in-
cluding the occurrence of branched 3-D structures. Furthermore, a number of addi-
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tional variable modifications, such as phosphorylation, sulfation, methylation and
acetylation, may be found on glycan residues. In addition to the complexity of the
glycan structure itself, glycoproteins typically exist as populations of diverse
glycoforms consisting of a number of different glycan chains attached to individ-
ual glycosylation sites in variable molar amounts (microheterogeneity).
N-glycosylation is a complex biosynthetic process which occurs in the secre-
tory pathway. A precursor oligosaccharide is initially attached to an asparagine res-
idue of an acceptor site and the carbohydrate structure is then formed by iterative
and consecutive steps of trimming and assembly. N-glycosylation requires the tri-
peptide Asn-X-Ser/Thr in the polypeptide chain, where Asn is the attachment point
and X may be any amino acid except proline or aspartic acid. N-glycans are com-
monly divided into three classes based on their structure and complexity: high
mannose type, hybrid type and complex type, although division into a fourth class,
paucimannosidic type, has been suggested.16
While most parts of the N-glycosylation process are common to all eukaryo-
tes, plants and invertebrates possess additional activities which generate structures
which are not present in mammalian glycans. N-linked carbohydrates containing
these structures,  (1,2)-xylose and (1,3)-fucose, are immunogenic and IgE anti-
body binding to plant and insect N-glycans was first reported by Aalberse et al.,17
more than two decades ago. Sialic acid, which occurs as a terminal structure in
mammalian N-glycans, has not been found in plants or invertebrates.
Due to the limited number of glyco structures in the proteins, they often con-
tribute to the IgE binding in different in vitro assays, where there is no necessity of
bridging two IgE molecules in order to promote the release of histamine from
basophiles, a feature designated as allergic reaction type I (IgE-mediated hyper-
sensitivity) with its typical clinical manifestations. However, the ability of a mole-
cule to bridge two IgE molecules could be investigated in a wide range of in vitro
and in vivo assays, such as histamine release or the typical skin prick assay.
Altough the need for elucidation of a glycocomponent emerges, there is still
no clear data on this, even from those assays made on neoglycoproteins (non-aller-
gic proteins coupled to a glycan originating from a glycoallergen).18
Therefore, a complete analysis of a single glycoprotein would have to provide in-
formation regarding microheterogeneity at each glycosylation site and a structural
characterization of the bound carbohydrate moieties. Very often the characterization of
a single glycoprotein isoform, e.g., separation by 2-DE, is sufficient to provide an
overview of the overall complexity of the sample. The relative ionization efficiency of
glycans during MALDI-MS has been demonstrated to be very similar.19 Using MS
techniques, it is possible to detect both the glycosylation sites and glycan structures, as
well as the individual glycan distribution at each glycosylation site (microheteroge-
neity). The method is based on gel-separated glycoproteins and is extremely sensitive.
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4. TERTIARY STRUCTURE AND FUNCTION
One of the very important aims regarding allergens is to reveal the structure and
function of these molecules. The introduction of molecular biology to the study of
allergen structure and function was initiated just over a decade ago. Since then, the
knowledge gained from these studies has made a major contribution to the study of
allergic disease. Most of the clinically significant allergens have now been described
at the molecular level and their endogenous biochemical activities determined.
The ultimate task in a thorough biochemical characterization of an allergen is
to determine its real 3D structure. The availability of recombinant proteins has
greatly facilitated the ability of crystallographers to determine the three-dimen-
sional structures of a variety of allergens. The 3D structure of numerous allergens
has been determed by X-ray crystallography.
One of the first published 3D structures of an allergen is the 3D structure of Bet v
1, the major allergen of birch pollen. The three-dimensional structure of the major birch
pollen allergen, the 17,500 M(r) acidic protein Bet v 1 (from the birch), was determined
both in the crystalline state by X-ray diffraction and in solution by nuclear magnetic res-
onance (NMR) spectroscopy. This was the first experimentally determined structure of a
clinically important major inhalant allergen. The structure shows three regions on the
molecular surface predicted to harbor cross-reactive epitopes. This provides a structural
basis for the allergic symptoms shown by birch pollen allergic patients when they en-
counter pollens from related trees, such as hazel, alder and hornbeam.20
The structure of Fel d 1 (the major allergen of cat dander), revealed by X-ray
crystallography, presents a striking similarity to that of uteroglobin, a steroid-indu-
cible cytokine-like molecule with anti-inflammatory and immunomodulatory pro-
perties.21 The structure of Fel d 1 displays the localization of three Fel d 1 IgE
binding epitopes on the surface of the protein. On the basis of the data obtained
from structural studies, there will be structural foundations for experiments to ver-
ify the antigenicity of the proposed epitopes, as well as to design novel hypoaller-
genic forms of the protein suitable for diagnosis and treatment of allergies.
The other method applied in solving the structures of allergens is NMR. Very re-
cently, the three-dimensional structure of Ole e 6 (a pollen protein from the olive tree)
was determined in solution by NMR methods.22 The global fold of Ole e 6 consists of
two nearly antiparalel alpha-helices, spanning residues 319 and 2333, which are
connected by a short loop and followed by a long, unstructured C-terminal tail.
When there is not enough protein available to crystallize it or when crystalli-
zation is very difficult (such as in the case of native, glycosylated proteins), it is
possible to peform some structural studies on a protein in solution, using methods
such as small angle X-ray scattering (SAXS)23 or by combining chemical cross-li-
nking, enzyme digestion and MS to obtain data on the low resultion surface topol-
ogy of a protein.24 However, these methods have so far not found wide application
in the characterization of allergens.
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Although it is reasonable to expect that the allergen molecule itself might influ-
ence modulation of the immune system, hitherto, there has been no definite evidence
for this. It is well established that Der p 1 is an active cystein protease. In vitro, this
enzyme cleaves CD25 and CD24 off the surface of lymphocytes and can also disrupt
tight junctions in epithelial cell layers.25,26 One of the panallergens, profilin, is an
actin-binding protein and is described from a variety of sources.2729 Profilins con-
stitute a ubiquitous family of proteins that control actin polymerization in eukaryotic
cells; in particular, profilin participates in the acrosomal reaction of animal sperm
cells. Plant profilins might have similar functions in pollens during plant fertilization
and, therefore, represent allergenic components in almost all pollens. Another ubiq-
uitous family of proteins, lipid transfer proteins, also represents allergens found in
wide range of plant sources, such as pollens and fruits.30,31
5. CROSS REACTIVITY OF POLLEN ALLERGENS AND CLASSIFICATION
Among the most important airborne allergens worldwide and in our coun-
try32–35 are proteins originating from pollen grains. The allergens of this origin are
well characterized, usually highly cross-reactive among members of the same
group and are classified into more than 10 different groups of allergens.
Group 1 allergens show 60  70 % sequence identity to expansins,36 a family
of proteins involved in cell wall loosening and extension in plants through their ac-
tivity of unlocking wall microfibril and matrix polysaccharide structures.37 In a
functional assay, group 1 pollen allergens from Phleum pratense, Lolium perenne
and Zea mays have indeed been found to posses expansin-like activity, and a
functional role of group 1 allergens in facilitating pollen tube growth through the
female flower tissue upon germination has been suggested.38 The family of
expansins has been divided into -and -expansins; the latter including group 1
grass pollen allergens, as well as members expressed in vegetative tissues.
A number of tree pollen and fruit allergens belong to the group of plant pro-
teins known as pathogenesis-related proteins (PRs). These proteins are either
constitutively expressed or produced in response to development signals, physical
stress and infection. There are currently 14 groups, with most of the denominated
allergens belonging to PR-2, -3, -4, -5-, -10 and -14.39
Enzymatic activity, particularly carbohydrases (PR-2, -3, -4) and ribonu-
cleases (PR-10), as well as thaumatin-like proteins (PR-5) characterize many of the
groups. The PR-5 thaumatin-like proteins demonstrate some homology with the
sweet-tasting protein thaumatin from the fruit of the plant Thaumatococcus da-
nielli, and at least four allergens have been shown to belong to this group, includ-
ing the cherry allergen Pru av 2,40 the apple allergen Mal d 241 and the kiwi aller-
gen Act c 2.4 However, the PR-5 proteins per se do not posses the property of
sweetness. Their true function in plants is unclear, although they have been shown
to possess antifungal properties.
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6. RECOMBINANT ALLERGENS
Commercial allergen extracts are routinely used for the diagnosis of allergic
diseases, both in vitro and in vivo. The evaluation of the quality of an allergen ex-
tract for testing means the demonstration of consistent protein and IgE-reactive
patterns, the quantification of the individual allergens, as well as a measurement of
total allergen-specific IgE-reactivity of the extract. The production of allergen ex-
tracts from natural sources of consistent quality places considerable demands on
manufactures.42
The outcome of in vitro IgE determiations and skin tests largely depends on
the quality of the extracts used.43 Complex allergenic sources, such as mites,
moulds and foodstuffs, represent heterogeneous mixtures containing hundreds of
proteins, carbohydrates, proteolytic enzymes and lower molecular weight compo-
nents, including histamine. For example, the quality of extracts from fruits, vegeta-
bles and other plant foods can vary due to the inherent presence of proteolytic en-
zymes of these allergen sources.44 This instability also leads to consistency prob-
lems with different lots of commercial extracts, or to large variations between ex-
tracts from different manufactures.
The driving force for moving into recombinant allergen technology was the
recognition of the possibility to formulate optimal preparations of diagnostic ap-
plications, as well as allergen-specific immunotherapy using recombinant aller-
gens and derivatives thereof.
The introduction of recombinant technology into the field of allergen charac-
terization has considerably improved knowledge on allergenic structures. The first
report on a genetically engineered allergen was reported in 1988. Since then an im-
pressive number of allergens from different allergenic sources have been ex-
pressed and characterized.
Starting from a cloned cDNA, the encoded gene product can be biotechnologi-
cally produced as a highly pure protein of consistent quality in almost unlimited
amounts. Therefore, a great number of allergenic molecules have been cloned,
characterized and tested clinically during the past decade.45 The results obtained
showed that recombinant allergens can, in some aspects, be superior to commer-
cially available extracts in terms of specificity and sensitivity for diagnostic pur-
poses.46 Nevertheless, before their application in diagnosis, structural/functional
features and immunological properties of recombinant allergens have to be evalu-
ated with their natural counterparts.
Although different expression systems have been employed for allergen ex-
pression, most of the existing recombinant alergens have been expressed in E. coli.
For example, almost all timothy grass pollen allergens, except Phl p 4, have, so far,
been expressed in E. coli.
In spite of the many advantages, prokaryotic recombinant allergens, on the
other hand, have some limitations: their tertiary structure may be incorrect and
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post-translational modifications, such as glycosylations (see above), which can be
important for correct folding and, if not correct, can lead to a lack of allergenicity.
Upon production, recombinant proteins are usually stored in inclusion bodies, so
their purification demands buffers with denaturing agents, such as 6 M guanidine
hydrochloride or 8 M urea. Correct refolding of allergens with a high content of
Cys residues (more than 6) can sometimes be a problem.
Apart from expression in bacteria, yeast systems are also used for allergen ex-
pression. Different allergens from grass pollen (Phl p 1, Dac g 1), cat dander (Fel d
1), and mite allergens (Der p 1, Der f 1) have been expressed in Pichia pastoris.
However, it has been shown that allergens expressed in P. pastoris are often
overglycolysated compared to their natural counterparts.
Easy transformation and cultivation make plants also suitable for the produc-
tion of many recombinant proteins. Plants are capable of carrying out not only
post-translational protein modifications required for the biological activity of
many eukaryotic proteins, such as glycosylation, but also acetylation, phospho-
rylation, and other modifications. Numerous heterologous (recombinant) proteins
have been produced in plant leaves, fruits, roots, tubers and seeds, and targeted to
different subcellular compartments, such as cytoplasm, endoplasmic reticulum, or
apoplastic space.
However, the extraction and purification of proteins from biochemically com-
plex plant tissues is a laborious and expensive process which is a major obstacle to
large-scale protein manufacture in plants.47
Foreign genes can be produced in plants by permanent insertion or by tran-
sient expression using virus-based vectors. Several alergens have been success-
fully produced via a tobacco mosaic virus (TMV) expression system, i.e., Bet v 1,
the major birch pollen allergen,48 Hev b 1 and Hev b 3, two Spina bifida associated
latex allergens,49 as well as the apple thaumatin-like protein Mal d 2.50
First studies investigating the IgE antibody reactivity of recombinant aller-
gens have shown that recombinant allergens resemble the IgE epitopes of natural
allergens and can be used for allergy diagnosis to determine the IgE reactivity pro-
file of a patient at the molecular level.51, 52
Recently published results from a multicenter clinical trial on the development
and evaluation of allergen-specific immunotherapy based on genetically engi-
neered allergens suggest that immunotherapy with genetically engineered allergen
derivatives has the potential to induce an allergen-specific, mixed Th2/Th1-like
immune response. This immune response was characterized by an initial induction
of IgE antibodies, followed by strong IgG1, IgG2, and IgG4 responses recognizing
new epitopes as well as epitopes defined by the disease-eliciting IgE antibodies.53
Therefore, in addition to application in component-resolved allergy diagnosis, ge-
netically engineered allergens may also be used for the treatment of most common
forms of allergy and even prophylactic vaccination.
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7. IMMUNOCHEMICAL CHARACTERIZATION OF ALLERGENS AND THEIR MODE OF
ACTION
Scientists involved in the research of allergic diseases and the understanding
of Type I hypersensitivity have been searching for the answer to one question: what
makes an antigen an allergen? In other words, which structural features make some
antigens provoke an IgE instead of an IgG immune response? Almost all allergens
which have been hitherto identified are proteins or glycoproteins by nature. More-
over, the surface structure (topology) is the most relevant for antibody binding.
Therefore, a lot of research has been focused on determining allergenic structures
and epitope mapping of IgE-binding epitopes.54,55
The term allergen is used to describe three distinct molecular features: to bind
IgE antibodies; to sensitize, which means to provoke the immune system to produce
high-affinity IgE antibodies; and to elicit allergic reactions i.e., to trigger allergic
symptoms in a sensitized person. In terms of these criteria, allergens can be divided
into: complete allergens which possess all these features, and incomplete allergens
which can elicit allergic symptoms but do not usually sensitize. This division mostly
refers to food allergens, since it is believed that proteins which survive the environ-
ment of proteolytic enzymes present in the gastrointestinal fluids, will retain suffi-
cient structural integrity to provoke the immune system, having passed the mucosal
barrier of the gastrointestinal tract. All inhalant allergens (tree, grass, and weed pol-
len allergens, house dust mite allergens) are considered as complete allergens, since
they encounter the immune system via the upper respiratory airways.
Several experiments can be performed to elucidate these features. Qualitative as-
says, such as dot blot or Western blot, are usually performed to validate whether the
protein of interest has the potential to bind IgE from the sera of an allergic patient.
Cross-linking of IgE antibodies on FcR1 by an allergen is the primary event
by which mediators are released from basophils and mast cells. Hence, an allergen
must possess at least two IgE binding epitopes in order to bridge two IgE mole-
cules anchored on FcR1 receptors and thus trigger allergic symptoms.
Another definition which has been introduced is the distinction between major
and minor allergens, as a criterion, which addresses the issue of allergenicity. The
definition of a major allergen is based on the prevalence of IgE or skin reactivity in
persons that are sensitized to the allergen. An allergen is considered as a major if
more than 50 % of the tested patients have allergen-specific IgE.
Molecular-level information on the structure of allergen indicates that aller-
gens are considerably heterogeneous protein structures and that there is no particu-
lar amino acid sequence which is responsible for the allergenicity.56
It is estimated that over 20 % of the world’s population suffer from IgE-medi-
ated allergic diseases, such as asthma, rhinoconjunctivitis, eczema, and anaphy-
laxis. Therefore, the information gained from detailed structural, functional and
immunochemical studies of these intriguing molecules that nowadays modulate a
METHODS FOR ALLERGEN CHARACTERIZATION 357
variety of pathophysiological conditions, would greatly improve our understand-
ing of the underlying disease mechanisms, and the way to handle them. All the ef-
forts put into this would certainly improve our ability to handle the disease, both in
a diagnostic and a therapeutical sense. The further development of (bio)chemical
methods which could find application in any of the above mentioned aspects of al-
lergen charcterization would help in reaching the goal  knowing better, control-
ling better and, maybe, one day... treating better allergies.
I Z V O D
PREGLED NAJ^E[]E KORI[]ENIH METODA U KARAKTERIZACIJI
ALERGENA
TAWA ]IRKOVI] VELI^KOVI], MARIJA GAVROVI]–JANKULOVI] i RATKO M. JANKOV
Hemijski fakultet, Univerzitet u Beogradu, Studentski trg 16, 11000 Beograd
Okarakterisati alergen je te`ak i mukotrpan zadatak, jer zahteva preciznu bio-
hemijsku karakterizaciju (gliko)proteinskog molekula, kao i ustanovqavawe wegove
sposobnosti da vezuje IgE, jer je to glavna spona ka osloba|awu histamina u nekim
stawima preosetqivosti (alergije tipa I). Karakterizacija alergena podrazumeva odre-
|ivawe molekulske mase, odre|ivawe strukture, fizikohemijskih svojstava, IgE vezu-
ju}ih osobina i wegovu alergenost. Ovaj rad daje pregled koje se biohemijske i imu-
nohemijske metode naj~e{}e koriste radi postizawa tog ciqa. Informacije koje su do
sada dobijene o strukturi alergena pokazuju da su ovi molekuli izuzetno heterogene
strukture i da ne postoji odre|ena aminokiselinska sekvencija koja bi mogla da predvi-
di alergenost datog molekula. Me|utim, informacije dobijene iz detaqnih struktur-
nih studija ovih molekula }e doprineti na{em razumevawu patofiziolo{kih procesa
koji su u osnovi alergijskih oboqewa i unapredi}e na~in na koji ih tretiramo.
(Primqeno 28. decembra 2004)
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